ReviewJACC. Basic to translational science2019
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis.
Review in JACC. Basic to translational science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis.BMC cardiovascular disorders · 2021Pooled it
- A simple nomogram to help guide the diagnosis of cardiac amyloidosis in patients with heart failure with preserved ejection fraction.Quantitative imaging in medicine and surgery · 2026Article
- Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies.Current cardiology reports · 2025Review
- Detection of cardiac amyloidosis on routine bone scintigraphy: an important gatekeeper role for the nuclear medicine physician.The international journal of cardiovascular imaging · 2024Article
- Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy.Heart failure reviews · 2024Review
- Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis.Heart international · 2024Review
- Conformational inhibitors of protein aggregation.Current opinion in structural biology · 2023Review
- Transthyretin cardiac amyloidosis.Cardiovascular research · 2023Article
- Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy.Global heart · 2023Article
- Histologic Diagnosis of Coronary Amyloidosis Using Percutaneous Transluminal Directional Atherectomy.CJC open · 2023Article
- A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan.Scientific reports · 2022Article
- Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC).European journal of heart failure · 2022Article
- Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy.Frontiers in cardiovascular medicine · 2022Article
- Reproducibility and repeatability of assessment of myocardial light chain amyloidosis burden usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Potential Cardiac Amyloid PET/CT Imaging Targets for Differentiating Immunoglobulin Light Chain From Transthyretin Amyloidosis.Current cardiology reports · 2021Review
- Gastrointestinal amyloidosis: A focused review.World journal of gastrointestinal endoscopy · 2021Review
- From Clinical Clues to Final Diagnosis: The Return of Detective Work to Clinical Medicine in Cardiac Amyloidosis.Frontiers in cardiovascular medicine · 2021Article
- Recent advances in the diagnosis and management of amyloid cardiomyopathy.Faculty reviews · 2021Review
- Cardiac Amyloidosis: More Than a Needle in a Haystack.JACC. CardioOncology · 2020Article
- Diagnosis and treatment of transthyretin-related amyloidosis cardiomyopathy.Clinical cardiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyretin (ATTR) amyloidosis have been limited. However, there are now multiple novel therapeutics in development and several therapeutics recently approved that promise to revolutionize clinical management of AL and ATTR. Most of these agents disrupt specific stages of amyloidogenesis such as light chain or transthyretin protein production, formation of amyloidogenic intermediates, or amyloid fibril aggregation. Others aim to remove existing amyloid tissue deposits using monoclonal antibody technology. Although these advances represent an important step forward in the care of cardiac amyloidosis patients, additional studies are needed to define the optimal treatment paradigms for AL and ATTR and to validate clinical, imaging, or serum biomarker strategies that may confirm a cardiac response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.